Experience

Davis Polk advised the underwriters and joint global coordinators in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on…

Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering of 6,250,000 ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of its ordinary shares to raise gross proceeds of approximately €80…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an $88 million SEC-registered follow-on offering of 2,875,000…

Davis Polk advised the underwriters in connection with the $90 million initial public offering of common stock by Kodiak Sciences Inc. The common stock is listed on the NASDAQ Global Market…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 7,500,000 shares of common stock of…

Davis Polk advised the bookrunner in connection with the initial public offering of Cipla Quality Chemical Industries Limited on the Uganda Securities Exchange. The offering consisted of…

Davis Polk advised Shire plc on concurrent tender offers by Baxalta Incorporated and Shire Acquisitions Investments Ireland DAC (“SAIIDAC”), both wholly owned subsidiaries of Shire,…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of $6 billion aggregate principal amount of senior notes in four…

Davis Polk advised the representatives of the several underwriters in connection with Galapagos NV’s offering of 2,961,373 ordinary shares in the form of American depositary shares, which…